Related Experiment Video

Updated: Dec 26, 2025

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

6.8K

The Atypical Protein Kinase C Small Molecule Inhibitor ζ-Stat, and Its Effects on Invasion Through Decreases in PKC-ζ

Tracess Smalley1, Rainer Metcalf1, Rekha Patel1

  • 1Department of Chemistry, University of South Florida, Tampa, FL, United States.

Frontiers in Oncology
|March 17, 2020
PubMed

Insights

The small molecule inhibitor ζ-Stat shows promise for treating clear cell ovarian carcinoma (CCOC). It effectively reduces cancer cell invasion by targeting the PKC-ζ signaling pathway, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer, particularly epithelial ovarian carcinomas (EOC), is a significant health concern with high mortality rates.
  • Clear cell ovarian carcinoma (CCOC) is an aggressive, non-serous subtype of EOC.
  • Protein kinase C (PKC) family, especially atypical isoforms (aPKC) like PKC-ι and PKC-ζ, are implicated in cancer progression, invasion, and metastasis.

Purpose of the Study:

  • To investigate the therapeutic potential of the novel aPKC inhibitor ζ-Stat in clear cell ovarian carcinoma (CCOC).
  • To elucidate the binding mechanisms of ζ-Stat and its effect on the PKC-ζ signaling cascade.
  • To assess the disruption of invasion and migration in CCOC by ζ-Stat.

Main Methods:

  • Molecular docking and virtual target screening were employed to understand ζ-Stat's interactions.
  • Western blot analysis, end-point PCR, and GST pull-down assays were used to examine protein pathways.
  • Cell viability, invasion, and migration assays were conducted to evaluate ζ-Stat's functional effects.

Main Results:

  • The small molecule inhibitor ζ-Stat demonstrated potential as a therapeutic candidate for CCOC.
  • ζ-Stat was found to decrease the activation of the PKC-ζ/Ect2/Rac1 pathway.
  • This targeted pathway inhibition led to a significant reduction in the invasive behavior of CCOC cells.

Conclusions:

  • ζ-Stat is a promising drug candidate for the potential treatment of clear cell ovarian carcinoma.
  • Targeting the PKC-ζ signaling cascade with inhibitors like ζ-Stat can effectively decrease cancer cell invasion.
  • Further investigation into ζ-Stat's therapeutic potential in CCOC is warranted.
Keywords:
Ect2PKC-zetaPKC-ζclear cell ovarian carcinoma (CCOC)computational molecular modelingzeta-Statζ-Stat

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.4K
The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior08:12

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

Published on: June 12, 2019

5.4K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.8K